Regenxbio Inc

Research Regenxbio Inc (RGNX) on Bullrun: market cap USD 611.58M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRGNX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 611.58M
• Financial periodFY2025
• RevenueUSD 170.44M
• Revenue growth104.5%
• Net income-USD 193.88M
• Free cash flow-USD 126.38M

Valuation Snapshot

latest market cap is USD 611.58M.

About Regenxbio Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases;

Frequently asked questions

What is Regenxbio Inc's market cap?

Regenxbio Inc's market capitalization is USD 611.58M.

What does Regenxbio Inc do?

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.